{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:51:30Z","timestamp":1783659090622,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"DOI":"10.1186\/s12868-026-01004-7","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:08:19Z","timestamp":1776852499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preventive effect of PC-SOD on oxaliplatin-induced peripheral neuropathy in rats"],"prefix":"10.1186","volume":"27","author":[{"given":"Zhiwei","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Uchihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Tsukiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"8","key":"1004_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","volume":"20","author":"MB Lustberg","year":"2023","unstructured":"Lustberg MB, et al. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527\u201342.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1004_CR2","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/S1470-2045(17)30182-1","volume":"18","author":"M Das","year":"2017","unstructured":"Das M. Treating chemotherapy-induced peripheral neuropathy. Lancet Oncol. 2017;18(4):e202.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1004_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","volume":"160","author":"LA Colvin","year":"2019","unstructured":"Colvin LA. Chemotherapy-induced peripheral neuropathy: where are we now? Pain. 2019;160(Suppl 1):S1\u201310.","journal-title":"Pain"},{"issue":"1","key":"1004_CR4","first-page":"33","volume":"30","author":"C Teng","year":"2022","unstructured":"Teng C, et al. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. Support Care Cancer. 2022;30(1):33\u201347.","journal-title":"Support Care Cancer"},{"issue":"28","key":"1004_CR5","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325\u201348.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1004_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2013a GERCOR study. J Clin Oncol. 2006;24(3):394\u2013400.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1004_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.expneurol.2011.02.019","volume":"229","author":"J Boyette-Davis","year":"2011","unstructured":"Boyette-Davis J, Dougherty PM. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol. 2011;229(2):353\u20137.","journal-title":"Exp Neurol"},{"issue":"4","key":"1004_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpainsymman.2019.06.018","volume":"58","author":"XS Wang","year":"2019","unstructured":"Wang XS, et al. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019;58(4):662\u201371.","journal-title":"J Pain Symptom Manage"},{"key":"1004_CR9","doi-asserted-by":"crossref","unstructured":"Pfeiffer P et al. Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A\/POLAR-M). JNCI Cancer Spectr, 2022. 6(6).","DOI":"10.1093\/jncics\/pkac075"},{"key":"1004_CR10","doi-asserted-by":"publisher","first-page":"174480691984009","DOI":"10.1177\/1744806919840098","volume":"15","author":"HS Shim","year":"2019","unstructured":"Shim HS, et al. Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain. 2019;15:1744806919840098.","journal-title":"Mol Pain"},{"key":"1004_CR11","doi-asserted-by":"crossref","unstructured":"Canta A et al. Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity. Antioxid (Basel), 2020. 9(7).","DOI":"10.3390\/antiox9070594"},{"issue":"2","key":"1004_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/ALN.0b013e3181ca31bd","volume":"112","author":"HK Kim","year":"2010","unstructured":"Kim HK, et al. Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology. 2010;112(2):432\u20139.","journal-title":"Anesthesiology"},{"issue":"5","key":"1004_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jpain.2008.01.335","volume":"9","author":"EK Joseph","year":"2008","unstructured":"Joseph EK, et al. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain. 2008;9(5):463\u201372.","journal-title":"J Pain"},{"issue":"3","key":"1004_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0891-5849(94)90079-5","volume":"17","author":"C Michiels","year":"1994","unstructured":"Michiels C, et al. Importance of Se-glutathione peroxidase, catalase, and Cu\/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med. 1994;17(3):235\u201348.","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"1004_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0891-5849(02)00905-X","volume":"33","author":"IN Zelko","year":"2002","unstructured":"Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33(3):337\u201349.","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"1004_CR16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0022-3565(25)24056-3","volume":"271","author":"R Igarashi","year":"1994","unstructured":"Igarashi R, et al. Lecithinized superoxide dismutase enhances its pharmacologic potency by increasing its cell membrane affinity. J Pharmacol Exp Ther. 1994;271(3):1672\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1004_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1124\/jpet.108.144451","volume":"328","author":"T Ishihara","year":"2009","unstructured":"Ishihara T, et al. Therapeutic effect of lecithinized superoxide dismutase against colitis. J Pharmacol Exp Ther. 2009;328(1):152\u201364.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1004_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1378\/chest.11-2879","volume":"142","author":"KI Tanaka","year":"2012","unstructured":"Tanaka KI, et al. Effects of lecithinized superoxide dismutase and\/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest. 2012;142(4):1011\u20139.","journal-title":"Chest"},{"issue":"2","key":"1004_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1165\/rcmb.2016-0158OC","volume":"56","author":"KI Tanaka","year":"2017","unstructured":"Tanaka KI, et al. Evaluation of Lecithinized Superoxide Dismutase for the Prevention of Acute Respiratory Distress Syndrome in Animal Models. Am J Respir Cell Mol Biol. 2017;56(2):179\u201390.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"1004_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jconrel.2005.10.022","volume":"110","author":"M Takenaga","year":"2006","unstructured":"Takenaga M, et al. Lecithinized superoxide dismutase (PC-SOD) improved spinal cord injury-induced motor dysfunction through suppression of oxidative stress and enhancement of neurotrophic factor production. J Control Release. 2006;110(2):283\u20139.","journal-title":"J Control Release"},{"issue":"3","key":"1004_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/01.STR.0000257978.70312.1d","volume":"38","author":"T Tsubokawa","year":"2007","unstructured":"Tsubokawa T, et al. Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke. 2007;38(3):1057\u201362.","journal-title":"Stroke"},{"issue":"1","key":"1004_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-2125.2007.02965.x","volume":"65","author":"FJ Broeyer","year":"2008","unstructured":"Broeyer FJ, et al. The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. Br J Clin Pharmacol. 2008;65(1):22\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1004_CR23","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/jps.24031","volume":"103","author":"T Ishihara","year":"2014","unstructured":"Ishihara T, Nara S, Mizushima T. Interactions of lecithinized superoxide dismutase with serum proteins and cells. J Pharm Sci. 2014;103(7):1987\u201394.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1004_CR24","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0022-3565(25)10921-X","volume":"262","author":"R Igarashi","year":"1992","unstructured":"Igarashi R, et al. Lecithinization of superoxide dismutase potentiates its protective effect against Forssman antiserum-induced elevation in guinea pig airway resistance. J Pharmacol Exp Ther. 1992;262(3):1214\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1004_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11418-017-1113-6","volume":"71","author":"T Suzuki","year":"2017","unstructured":"Suzuki T, et al. Effect of ninjin\u2019yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice. J Nat Med. 2017;71(4):757\u201364.","journal-title":"J Nat Med"},{"key":"1004_CR26","doi-asserted-by":"crossref","unstructured":"Yi JM et al. Neuroprotective Effects of an Aqueous Extract of Forsythia viridissima and Its Major Constituents on Oxaliplatin-Induced Peripheral Neuropathy. Molecules, 2019. 24(6).","DOI":"10.3390\/molecules24061177"},{"issue":"4","key":"1004_CR27","first-page":"837","volume":"10","author":"R Cece","year":"1995","unstructured":"Cece R, et al. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol. 1995;10(4):837\u201345.","journal-title":"Histol Histopathol"},{"issue":"10","key":"1004_CR28","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1523\/JNEUROSCI.23-10-04117.2003","volume":"23","author":"K Obata","year":"2003","unstructured":"Obata K, et al. Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. J Neurosci. 2003;23(10):4117\u201326.","journal-title":"J Neurosci"},{"key":"1004_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-2105-14-219","volume":"14","author":"J Sun","year":"2013","unstructured":"Sun J, et al. TCC: an R package for comparing tag count data with robust normalization strategies. BMC Bioinformatics. 2013;14:219.","journal-title":"BMC Bioinformatics"},{"issue":"43","key":"1004_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1004_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"6","key":"1004_CR32","doi-asserted-by":"publisher","first-page":"104810","DOI":"10.1016\/j.jbc.2023.104810","volume":"299","author":"K Etoh","year":"2023","unstructured":"Etoh K, Nakao M. A web-based integrative transcriptome analysis, RNAseqChef, uncovers the cell\/tissue type-dependent action of sulforaphane. J Biol Chem. 2023;299(6):104810.","journal-title":"J Biol Chem"},{"issue":"2","key":"1004_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jphs.2018.06.008","volume":"137","author":"T Kawashiri","year":"2018","unstructured":"Kawashiri T, et al. Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro. J Pharmacol Sci. 2018;137(2):202\u201311.","journal-title":"J Pharmacol Sci"},{"key":"1004_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.irn.2019.05.001","volume":"145","author":"A Trecarichi","year":"2019","unstructured":"Trecarichi A, Flatters SJL. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy. Int Rev Neurobiol. 2019;145:83\u2013126.","journal-title":"Int Rev Neurobiol"},{"key":"1004_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fphar.2013.00156","volume":"4","author":"Y Han","year":"2013","unstructured":"Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol. 2013;4:156.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1004_CR36","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/0008-5472.CAN-17-1467","volume":"78","author":"KM Wozniak","year":"2018","unstructured":"Wozniak KM, et al. Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. Cancer Res. 2018;78(3):817\u201329.","journal-title":"Cancer Res"},{"key":"1004_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.expneurol.2014.06.016","volume":"261","author":"C Di Mannelli","year":"2014","unstructured":"Di Mannelli C. Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol. 2014;261:22\u201333.","journal-title":"Exp Neurol"},{"key":"1004_CR38","doi-asserted-by":"publisher","first-page":"174480691772625","DOI":"10.1177\/1744806917726256","volume":"13","author":"J Wang","year":"2017","unstructured":"Wang J, et al. Upregulation of CX3CL1 mediated by NF-\u03baB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration. Mol Pain. 2017;13:1744806917726256.","journal-title":"Mol Pain"},{"issue":"10","key":"1004_CR39","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.7150\/thno.54793","volume":"11","author":"SJ Chen","year":"2021","unstructured":"Chen SJ, et al. Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy. Theranostics. 2021;11(10):4672\u201387.","journal-title":"Theranostics"},{"issue":"1","key":"1004_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12868-024-00891-y","volume":"25","author":"K \u00c1lvarez-Tosco","year":"2024","unstructured":"\u00c1lvarez-Tosco K, et al. Dorsal root ganglion inflammation by oxaliplatin toxicity: DPEP1 as possible target for peripheral neuropathy prevention. BMC Neurosci. 2024;25(1):44.","journal-title":"BMC Neurosci"},{"issue":"12","key":"1004_CR41","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2326-6066.CIR-22-0197","volume":"10","author":"T Lin","year":"2022","unstructured":"Lin T, et al. NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy. Cancer Immunol Res. 2022;10(12):1542\u201358.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"1004_CR42","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/acn3.51691","volume":"9","author":"A Calls","year":"2022","unstructured":"Calls A, et al. A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice. Ann Clin Transl Neurol. 2022;9(12):1985\u201398.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"1004_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/WNR.0000000000001802","volume":"33","author":"M Wang","year":"2022","unstructured":"Wang M, et al. Duloxetine alleviates oxaliplatin-induced peripheral neuropathy by regulating p53-mediated apoptosis. NeuroReport. 2022;33(10):437\u201344.","journal-title":"NeuroReport"},{"key":"1004_CR44","doi-asserted-by":"crossref","unstructured":"Yamada T, et al. Lecithinized superoxide dismutase prevents oxaliplatin-induced peripheral neuropathy: a double-blind, placebo-controlled, randomized phase II study. Volume 10. ESMO Gastrointestinal Oncology; 2025. p. 100269.","DOI":"10.1016\/j.esmogo.2025.100269"},{"issue":"9","key":"1004_CR45","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ejca.2011.08.009","volume":"48","author":"S Ushio","year":"2012","unstructured":"Ushio S, et al. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer. 2012;48(9):1407\u201313.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"1004_CR46","first-page":"S38","volume":"5","author":"A Grothey","year":"2005","unstructured":"Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5(Suppl 1):S38\u201346.","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"1004_CR47","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1021\/acschemneuro.8b00013","volume":"9","author":"S Toyama","year":"2018","unstructured":"Toyama S, et al. Protective Effect of a Mitochondria-Targeted Peptide against the Development of Chemotherapy-Induced Peripheral Neuropathy in Mice. ACS Chem Neurosci. 2018;9(7):1566\u201371.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"1004_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12640-009-9127-9","volume":"18","author":"I Cervellini","year":"2010","unstructured":"Cervellini I, et al. The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. Neurotox Res. 2010;18(2):151\u201360.","journal-title":"Neurotox Res"},{"issue":"12","key":"1004_CR49","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.jpain.2013.08.002","volume":"14","author":"C Di Mannelli","year":"2013","unstructured":"Di Mannelli C. Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J Pain. 2013;14(12):1585\u2013600.","journal-title":"J Pain"},{"issue":"27","key":"1004_CR50","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/pnas.1305321110","volume":"110","author":"JA Sprowl","year":"2013","unstructured":"Sprowl JA, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013;110(27):11199\u2013204.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1004_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12906-016-1396-2","volume":"16","author":"ES Cho","year":"2016","unstructured":"Cho ES, et al. Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo models. BMC Complement Altern Med. 2016;16(1):419.","journal-title":"BMC Complement Altern Med"},{"key":"1004_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fphar.2017.00344","volume":"8","author":"X Cheng","year":"2017","unstructured":"Cheng X, et al. Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients. Front Pharmacol. 2017;8:344.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1004_CR53","doi-asserted-by":"publisher","first-page":"e0128080","DOI":"10.1371\/journal.pone.0128080","volume":"10","author":"C Di Mannelli","year":"2015","unstructured":"Di Mannelli C. Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS ONE. 2015;10(6):e0128080.","journal-title":"PLoS ONE"},{"issue":"12","key":"1004_CR54","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41568-025-00863-2","volume":"25","author":"P Karschnia","year":"2025","unstructured":"Karschnia P, Nelson TA, Dietrich J. Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity. Nat Rev Cancer. 2025;25(12):887\u2013909.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1004_CR55","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00280-020-04135-8","volume":"86","author":"M Kotaka","year":"2020","unstructured":"Kotaka M, et al. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. Cancer Chemother Pharmacol. 2020;86(5):607\u201318.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1004_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1248\/yakushi.13-00221-4","volume":"134","author":"T Mizushima","year":"2014","unstructured":"Mizushima T. [Development of lecithinized superoxide dismutase as a drug for IPF]. Yakugaku Zasshi. 2014;134(1):69\u201376.","journal-title":"Yakugaku Zasshi"},{"issue":"1","key":"1004_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0021-5198(19)31433-7","volume":"74","author":"Y Hori","year":"1997","unstructured":"Hori Y, et al. Effect of lecithinized-superoxide dismutase on the rat colitis model induced by dextran sulfate sodium. Jpn J Pharmacol. 1997;74(1):99\u2013103.","journal-title":"Jpn J Pharmacol"},{"issue":"4 Pt 1","key":"1004_CR58","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1164\/ajrccm.161.4.9906099","volume":"161","author":"K Tamagawa","year":"2000","unstructured":"Tamagawa K, et al. Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1279\u201384.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1004_CR59","doi-asserted-by":"publisher","first-page":"L348","DOI":"10.1152\/ajplung.00289.2009","volume":"298","author":"K Tanaka","year":"2010","unstructured":"Tanaka K, et al. Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;298(3):L348\u201360.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"1004_CR60","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0091270007309705","volume":"48","author":"J Suzuki","year":"2008","unstructured":"Suzuki J, et al. Pharmacokinetics of PC-SOD, a lecithinized recombinant superoxide dismutase, after single- and multiple-dose administration to healthy Japanese and Caucasian volunteers. J Clin Pharmacol. 2008;48(2):184\u201392.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1004_CR61","first-page":"596","volume":"57","author":"R Chen","year":"2019","unstructured":"Chen R, et al. Pharmacokinetics and safety of PC-SOD, a lecithinized recombinant superoxide dismutase, in healthy Chinese subjects: A phase 1, randomized, placebo-controlled, dose-escalation study Int. J Clin Pharmacol Ther. 2019;57(12):596\u2013602.","journal-title":"J Clin Pharmacol Ther"},{"issue":"9","key":"1004_CR62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1463-1318.2008.01487.x","volume":"10","author":"Y Suzuki","year":"2008","unstructured":"Suzuki Y, et al. A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. Colorectal Dis. 2008;10(9):931\u20134.","journal-title":"Colorectal Dis"},{"issue":"3","key":"1004_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1124\/jpet.111.179051","volume":"338","author":"K Tanaka","year":"2011","unstructured":"Tanaka K, et al. Therapeutic effect of lecithinized superoxide dismutase on pulmonary emphysema. J Pharmacol Exp Ther. 2011;338(3):810\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"1004_CR64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","volume":"596","author":"VA Carozzi","year":"2015","unstructured":"Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett. 2015;596:90\u2013107.","journal-title":"Neurosci Lett"},{"issue":"19","key":"1004_CR65","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1002\/cncr.28234","volume":"119","author":"AA Argyriou","year":"2013","unstructured":"Argyriou AA, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013;119(19):3570\u20137.","journal-title":"Cancer"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12868-026-01004-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-026-01004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-026-01004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:03:30Z","timestamp":1780538610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12868-026-01004-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1186\/s12868-026-01004-7","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the ARRIVE guidelines and in compliance with relevant institutional and national regulations for the care and use of laboratory animals. The experimental protocols in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of the Shonan Health Innovation Park (Shonan iPark).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Tohru Mizushima PhD, president and CEO, Koichiro Fukuda PhD, board director, Zhiwei Qiao PhD, Shota Akimoto, Noriko Kaji PhD, Yuki Uchihara PhD and Naohiro Tsukiyama, employees of LTT Bio-Pharma Co., LTD. LTT Bio-Pharma is the developer of PC-SOD. Tohru Mizushima PhD owns stock in LTT Bio-Pharma Co., LTD.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}